| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ... The lancet oncology 15 (12), e538-e548, 2014 | 5590 | 2014 |
| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 2896 | 2016 |
| Daratumumab, lenalidomide, and dexamethasone for multiple myeloma MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ... New England Journal of Medicine 375 (14), 1319-1331, 2016 | 1702 | 2016 |
| Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1 … JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak, M Agha, AD Cohen, ... The Lancet 398 (10297), 314-324, 2021 | 1285 | 2021 |
| Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial S Lonial, BM Weiss, SZ Usmani, S Singhal, A Chari, NJ Bahlis, A Belch, ... The Lancet 387 (10027), 1551-1560, 2016 | 1033 | 2016 |
| Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ... Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016 | 1024 | 2016 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 1004 | 2019 |
| Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ... The lancet oncology 21 (2), 207-221, 2020 | 809 | 2020 |
| Teclistamab in relapsed or refractory multiple myeloma P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ... New England Journal of Medicine 387 (6), 495-505, 2022 | 741 | 2022 |
| Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy UH Gandhi, RF Cornell, A Lakshman, ZJ Gahvari, E McGehee, ... Leukemia 33 (9), 2266-2275, 2019 | 589 | 2019 |
| Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group M Cavo, E Terpos, C Nanni, P Moreau, S Lentzsch, S Zweegman, ... The lancet oncology 18 (4), e206-e217, 2017 | 531 | 2017 |
| Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma SZ Usmani, BM Weiss, T Plesner, NJ Bahlis, A Belch, S Lonial, ... Blood, The Journal of the American Society of Hematology 128 (1), 37-44, 2016 | 519 | 2016 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 472 | 2016 |
| International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders J Hillengass, S Usmani, SV Rajkumar, BGM Durie, MV Mateos, S Lonial, ... The lancet oncology 20 (6), e302-e312, 2019 | 462 | 2019 |
| Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up T Martin, SZ Usmani, JG Berdeja, M Agha, AD Cohen, P Hari, D Avigan, ... Journal of Clinical Oncology 41 (6), 1265-1274, 2023 | 459 | 2023 |
| Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents SZ Usmani, C Heuck, A Mitchell, J Szymonifka, B Nair, A Hoering, ... haematologica 97 (11), 1761, 2012 | 451 | 2012 |
| Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group C Fernández de Larrea, RA Kyle, BGM Durie, H Ludwig, S Usmani, ... Leukemia 27 (4), 780-791, 2013 | 448 | 2013 |
| Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement MA Dimopoulos, J Hillengass, S Usmani, E Zamagni, S Lentzsch, ... Journal of Clinical Oncology 33 (6), 657-664, 2015 | 443 | 2015 |
| Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised … M Dimopoulos, H Quach, MV Mateos, O Landgren, X Leleu, D Siegel, ... The Lancet 396 (10245), 186-197, 2020 | 432 | 2020 |
| B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches N Shah, A Chari, E Scott, K Mezzi, SZ Usmani Leukemia 34 (4), 985-1005, 2020 | 416 | 2020 |
